Progress in Neuroscience Pipeline
Vistagen has made significant progress in its neuroscience pipeline with five clinical-stage pherine product candidates, each showing potential therapeutic benefits and favorable safety profiles.
Phase III Development for Fasedienol
Fasedienol is in Phase III development for the acute treatment of social anxiety disorder (SAD), a condition affecting over 31 million U.S. adults, with PALISADE-3 and PALISADE-4 trials ongoing and top-line results expected soon.
Advancements in Women's Health
PH80, a pherine product candidate for women's health indications, is advancing as a potential hormone-free treatment for menopausal hot flashes and has shown positive signals in other women's health conditions.
Strong Financial Position
As of March 31, 2025, Vistagen had $80.5 million in cash, cash equivalents, and moderate securities, providing a solid financial base for ongoing and future developments.